I have been thinking for some time what flow rate MMSCFPD is considered to be commercial so I emailed Neil last night.
I can say this, EXR have not formally advised the market what they consider would be a commercial rate at DD-2 but they will certainly be commenting on this in the months to come.
Many factors feed into this: gas price; transmission costs to market; expected production shape; opex; future well costs and savings over time; fiscal system; expected cost of capital. etc.
I think it will be far to say that Neil and the team are number crunching as we speak so that the day that the final flow rate calculation is determined they will be be able to declare if DD-2 is commercial and then inform the market.
IMO watch this space and enjoy the ride.
I can't think of a more exciting junior energy stock to be in right now!
- Forums
- ASX - By Stock
- EXR
- Ann: Daydream 2 Impressive Initial Flow Test
Ann: Daydream 2 Impressive Initial Flow Test, page-145
-
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EXR (ASX) to my watchlist
|
|||||
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $130.4M |
Open | High | Low | Value | Volume |
11.5¢ | 12.0¢ | 11.5¢ | $23.35K | 198.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 275069 | 11.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.0¢ | 154948 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 8333 | 0.120 |
5 | 275069 | 0.115 |
11 | 317080 | 0.110 |
8 | 517414 | 0.105 |
13 | 697511 | 0.100 |
Price($) | Vol. | No. |
---|---|---|
0.115 | 7744 | 3 |
0.120 | 179948 | 7 |
0.125 | 948933 | 7 |
0.130 | 286983 | 6 |
0.135 | 74000 | 2 |
Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
EXR (ASX) Chart |